RecruitingNot ApplicableNCT07208448

Voll Degradable Shoulder Spacer FIH Study

A Multi-Center, Prospective, First-In-Human Study to Evaluate the Initial Safety and Effectiveness of a Degradable Shoulder Spacer in Patients With Symptomatic Massive Rotator Cuff Tears


Sponsor

Voll Medical Technologies Ltd.

Enrollment

20 participants

Start Date

Dec 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The Voll Degradable Shoulder Spacer First-in-Human study aims to evaluate the initial safety, effectiveness, and clinical outcomes of a degradable shoulder spacer in over 50 years old patients with symptomatic massive rotator cuff tears (MRCT).


Eligibility

Min Age: 50 Years

Inclusion Criteria2

  • Full thickness MRCT.
  • Male or female patients ≥ fifty (50) years of age, in general good health, independent, and can comply with all post-operative evaluations and visits.

Exclusion Criteria2

  • Documented evidence of a history of drug/alcohol abuse within 1 year of enrollment.
  • Concurrent participation in any other investigational clinical study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVoll Degradable Shoulder Spacer

Voll Degradable Shoulder Spacer


Locations(4)

Assuta Ashdod Hospital

Ashdod, Israel

Ichilov (Sourasky Medical Center)

Tel Aviv, Israel

Humanitas Gavazzeni Castelli

Bergamo, Bergamo, Italy

Istituto Ortopedico Rizzoli

Bologna, Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07208448